Strattera Dose Titration After One Week
Increase to 80 mg immediately after one week at 40 mg, as this follows the FDA-approved titration schedule and represents the standard target dose for patients over 70 kg body weight or adults. 1
FDA-Approved Titration Schedule
The FDA label for Strattera provides explicit guidance on dose escalation for patients over 70 kg and adults:
- Initial dose: 40 mg daily for a minimum of 3 days 1
- Target dose: 80 mg daily after the initial period 1
- The 80 mg target can be administered as a single morning dose or divided into morning and late afternoon/evening doses 1
- After 2-4 additional weeks at 80 mg, the dose may be increased to a maximum of 100 mg if optimal response has not been achieved 1
There is no FDA recommendation for a 60 mg intermediate step in the standard titration protocol. 1
Important Clinical Considerations
Timing of Efficacy Assessment
- One week is insufficient to judge atomoxetine efficacy 2
- Patients should remain at the target dose of 80 mg for 4-6 weeks before determining treatment response 2
- Real-world data show that suboptimal dosing (averaging ~60 mg/day instead of the recommended 80 mg/day target) is associated with poor patient outcomes 2
Safety and Tolerability
- The 40 mg to 80 mg escalation after 3+ days is well-established and safe 1
- Research comparing fast titration (reaching 1.2 mg/kg over 3 days) versus slow titration (over 2+ weeks) showed that faster titration was associated with slightly higher rates of decreased appetite (14.3% vs 8.0%) and somnolence (14.3% vs 4.2%) in the first 2 weeks, but completion rates were similar 3
- Studies examining doses up to 120 mg/day in adults demonstrated good tolerability with no unexpected safety concerns 4
Evidence Against Higher Doses Beyond Standard Recommendations
- Two randomized trials in youth (ages 6-16) found no systematic advantage to increasing atomoxetine beyond standard guideline doses (up to 2.4-3.0 mg/kg/day) in patients with incomplete response 5
- Current dose recommendations of 80 mg/day target (maximum 100 mg/day) are appropriate for most patients 5
Critical Pitfalls to Avoid
Do not prematurely judge treatment failure at one week. Atomoxetine requires adequate time at target dose (4-6 weeks) before assessing efficacy 2. Setting appropriate patient expectations about the timeline for symptom improvement is essential to prevent premature discontinuation 2.
Monitor closely for suicidal ideation, particularly during dose changes. The FDA requires black box warnings about increased risk of suicidal ideation in children and adolescents, especially during the first few months of treatment or at times of dose adjustment 6, 1.
Assess for cardiovascular contraindications and monitor vital signs. Atomoxetine can cause modest increases in heart rate and blood pressure 6, 7. It is contraindicated in patients with severe cardiovascular disorders, pheochromocytoma, or narrow-angle glaucoma 1.